Tempus AI has expanded its strategic partnership with Bristol Myers Squibb (BMS) to optimise clinical trial designs across oncology and neuroscience programmes.
The collaboration seeks to use AI, multimodal real-world data, and data science methodologies to optimise trial design and improve the Probability of Technical & Regulatory Success (PTRS) in five initial programmes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Utilising Tempus’ Lens analytical platform, the companies are leveraging insights from an extensive collection of de-identified multimodal records to enhance clinical research and strengthen PTRS throughout BMS’s development portfolio.
The approach integrates large-scale real-world data with AI tools to test clinical assumptions, characterise patient populations, confirm control group criteria, and identify patient subgroups that could benefit from investigational therapies.
The initiative is initially supporting solid tumour oncology projects, focusing on indications such as colon, lung, and prostate cancers.
Beyond oncology, the collaboration also extends to neuroscience, particularly targeting Alzheimer’s disease. This demonstrates the application of Tempus’ multimodal database across a variety of therapeutic areas.
Tempus data and apps CEO Ryan Fukushima said: “Our collaboration with BMS aims to optimise clinical development by peering deeper into patient biology than ever before. Our multimodal data library allows us to connect the dots between clinical records and molecular subtypes. Together, we are doing more than just generating insights.
“We are uncovering the hidden biological signals of unmet patient need, which allows us to assess trial assumptions and stratify patient groups with unprecedented precision. We are moving past traditional approaches and creating a new level of data-driven confidence in the drug development process.”
BMS drug development strategy and innovation senior vice-president Bryan Campbell said: “This collaboration is about improving the quality of decisions we make in development, where the impact is greatest.
“By combining Tempus’ multimodal real-world data capabilities with our development expertise, we can rigorously pressure-test trial assumptions, better understand patient heterogeneity, and design studies with a higher probability of technical and regulatory success.”
Earlier this year, BMS announced positive top line results from the Phase III SCOUT-HCM trial assessing Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
